RxDoctor Payments Data

Amiel Moshfegh, MD

Vascular & Interventional Radiology · Commerce, CANPI 1144539644

Payments from drug & device makers

What this record shows

This record is dominated by other: $194,417 of the $201,880 with a category attached, or 96.3%. Angiodynamics, Inc. accounts for 96.5% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $82,067, more than ten times the $1,865 reported in 2019. Among vascular & interventional radiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$201,880in general payments, 2019–2025

Across 278 payments — averaging $726.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$195K
  • Abbott$4K
  • Philips North America LLC$1K
  • Medtronic$822
  • Boston Scientific$223
  • Veryan Medical Incorporated$166
  • plus $349 from 6 others

What the payments were for

  • Food & beverage$7,4634%
  • Other$194,41796%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$201,880 in reported general payments places this provider in the 95th percentile of 504 vascular & interventional radiology providers in California.

See all vascular & interventional radiology providers in California

Medicare billing

Part B allowed, 2024
$9,842,248
Medicare patients
844
Services billed
7,821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban12$14,095
ClopidogrelClopidogrel Bisulfate86$799

Paid to pharmacies, not to this prescriber.

Other vascular & interventional radiology in Commerce

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →